Please assess the completion status of the following clinical trial:

Trial Title: Immune Response to Influenza Vaccine in ESRD Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- ESRD patients aged 18 years or older, who had been treated for more than one month of either thrice weekly on-line hemodiafiltration (HDF) or conventional high flux hemodialysis (HD), with a session dialyzer urea clearance (Kt/V urea) of 1.2 and greater, with a convection volume target of 20 L/session for the HDF group~Exclusion Criteria:~* Had received any vaccination within the previous four weeks, or influenza vaccination within six months~* Patient who reported upper respiratory tract symptoms within three days prior to the study vaccination~* A history of allergy to influenza vaccine or egg~* Thrombocytopenia~* In receipt of immunosuppressant medications, chemotherapy, or had immunodeficiency

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hemodialysis (Type: ACTIVE_COMPARATOR): ESRD patients treated by hemodialysis
- Hemodiafiltration (Type: ACTIVE_COMPARATOR): ESRD patients treated by on-line hemodiafiltration

Based on this trial design, predict the completion outcome and termination type (if applicable).